Idera Pharmaceuticals Inc. (NASDAQ:IDRA) and Oragenics Inc. (NYSEAMERICAN:OGEN) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Idera Pharmaceuticals Inc.	N/A	96.39	62.66M	-2.48	0.00
Oragenics Inc.	N/A	0.00	10.03M	-1.45	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Idera Pharmaceuticals Inc. and Oragenics Inc.

Profitability

Table 2 shows the net margins, return on equity and return on assets of the two firms.

	Net Margins	Return on Equity	Return on Assets
Idera Pharmaceuticals Inc.	0.00%	-68.4%	-60.4%
Oragenics Inc.	0.00%	0%	-119.9%

Volatility & Risk

A 2.54 beta means Idera Pharmaceuticals Inc.’s volatility is 154.00% more than S&P 500’s volatility. Competitively, Oragenics Inc.’s beta is 1.71 which is 71.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Idera Pharmaceuticals Inc. are 8.2 and 8.2 respectively. Its competitor Oragenics Inc.’s Current Ratio is 9.9 and its Quick Ratio is 9.9. Oragenics Inc. can pay off short and long-term obligations better than Idera Pharmaceuticals Inc.

Analyst Recommendations

The Ratings and Recommendations for Idera Pharmaceuticals Inc. and Oragenics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Idera Pharmaceuticals Inc.	0	0	1	3.00
Oragenics Inc.	0	0	0	0.00

The consensus price target of Idera Pharmaceuticals Inc. is $14, with potential upside of 436.40%.

Insider & Institutional Ownership

Idera Pharmaceuticals Inc. and Oragenics Inc. has shares held by institutional investors as follows: 46.5% and 12.4%. 0.7% are Idera Pharmaceuticals Inc.’s share held by insiders. Competitively, Oragenics Inc. has 6.89% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Idera Pharmaceuticals Inc.	-2.74%	12.25%	-55.9%	-71.46%	-80.06%	2.53%
Oragenics Inc.	-3.3%	-5.68%	4.76%	106.04%	-46.01%	2.47%

For the past year Idera Pharmaceuticals Inc. has stronger performance than Oragenics Inc.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.